
News • CRISPR-Cas9-based approach
New laboratory tool to find better treatments for resistant melanomas
Researchers have developed a new lab model to study BAP1-deficient melanomas, a rare type of melanoma that evade the immune system once they metastasize and are resistant to current immunotherapies.
























